Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03862430 · ClinicalTrials.gov registry record · Phase 2
A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
A Phase 2 study of Glioblastoma Multiforme, sponsored by NuvOx.
- Active
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 12
- Study locations
NCT03862430: Active Phase 2 study of Glioblastoma Multiforme, sponsored by NuvOx.
NCT03862430 is a Phase 2 study of Glioblastoma Multiforme that is active but no longer recruiting, run by NuvOx. The registered enrollment target is 87 participants, roughly in line with the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target. The trial reports 12 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03862430, a Phase 2 study of Glioblastoma Multiforme, is active but no longer recruiting, sponsored by NuvOx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 12
- Study locations
Study Summary
This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.
Primary Outcome
To determine progression free survival (PFS) in newly-diagnosed glioblastoma patients after treatment with NVX-108 in combination with radiation and temozolomide (TMZ)
Conditions Studied
Interventions
- DRUG NanO2TM
- DRUG Placebo Saline Infusion
Study Locations (12)
Arizona
- Center for Neurosciences - Tucson
- University of Arizona - Tucson
California
- UC Irvine Health- Chao Family Comprehensive Cancer Center - Orange
- Providence St. John's Cancer Institute - Santa Monica
Connecticut
- Yale Cancer Center - New Haven
Illinois
- St. Francis Medical Center, OSF Healthcare - Peoria
Louisiana
- Ochsner Clinic Foundation - New Orleans
Missouri
- Saint Luke's Cancer Institute - Kansas City
New Jersey
- Atlantic Health System - Summit
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2023-03-31 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 2 |
What the registry record for NCT03862430 still lists
NCT03862430 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, roughly in line with the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target.
The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 2 interventions - of which NanO2TM is the first listed.
NCT03862430 lists 12 locations in 10 states (Arizona, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT03862430 about?
NCT03862430 is a clinical study titled "A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM". This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation ...
What is the current status of trial NCT03862430?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2023-03-31. Estimated completion is 2026-09-30.
What conditions does trial NCT03862430 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme.
What interventions are being tested in trial NCT03862430?
The interventions under investigation include: NanO2TM (DRUG), Placebo Saline Infusion (DRUG).
Who is sponsoring clinical trial NCT03862430?
This trial is sponsored by NuvOx, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03862430 being conducted?
This trial has 12 study locations across Arizona, California, Connecticut, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03862430's enrollment target sits among peer trials
87 22nd of 88 higher than 67 of 88 other Glioblastoma Multiforme trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma Multiforme trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
RECRUITING · Phase 2
-
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
-
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI